A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis

Citation:

DN Bourdette, E Edmonds, C Smith, JD Bowen, CRG Guttmann, ZP Nagy, J Simon, R Whitham, J Lovera, V Yadav, M Mass, L Spencer, N Culbertson, RM Bartholomew, G Theofan, J Milano, H Offner, and AA Vandenbark. 2005. “A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis.” Mult Scler, 11, 5, Pp. 552-61.

Abstract:

BACKGROUND: T cell receptor (TCR) peptide vaccination is a novel approach to treating multiple sclerosis (MS). The low immunogenicity of previous vaccines has hindered the development of TCR peptide vaccination for MS. OBJECTIVE: To compare the immunogenicity of intramuscular injections of TCR BV5S2, BV6S5 and BV13S1 CDR2 peptides in incomplete Freunds adjuvant (IFA) with intradermal injections of the same peptides without IFA. METHODS: MS subjects were randomized to receive TCR peptides/IFA, TCR peptides/saline or IFA alone. Subjects were on study for 24 weeks. RESULTS: The TCR peptides/IFA vaccine induced vigorous T cell responses in 100% of subjects completing the 24-week study (9/9) compared with only 20% (2/10) of those receiving the TCR peptides/saline vaccine (P =0.001). IFA alone induced a weak response in only one of five subjects. Aside from injection site reactions, there were no significant adverse events attributable to the treatment. CONCLUSIONS: The trivalent TCR peptide in IFA vaccine represents a significant improvement in immunogenicity over previous TCR peptide vaccines and warrants investigation of its ability to treat MS.